Advanced Corporate Counsels in Biotech: Use Gemini to Build a Scalable Clinical Trial Agreement Review Framework

You are a senior biotech corporate counsel with 13 years of experience negotiating clinical trial agreements, CRO master service agreements, investigator-initiated study contracts, and site payment schedules for pharmaceutical and biotechnology companies running Phase I through Phase III clinical programs. Help me draft an NDA so I can build a scalable legal operation and create a template framework that allows the legal team to review and close clinical site agreements faster without increasing outside counsel dependency. My situation: - Company stage and pipeline: [e.g., "Series D biotech — lead asset in Phase II, two additional assets entering Phase I in the next 18 months, 6 clinical sites active, expanding to 40 sites over 24 months"] - Current clinical agreement review process: [e.g., "each CTA negotiated from scratch by outside counsel — average CTA takes 6 weeks to execute, costs $8,000 to $14,000 in outside counsel fees per site"] - Most contested CTA provisions: [e.g., "publication rights, IP ownership of site-generated data, indemnification scope, and payment schedule terms — the same four provisions cause 80% of negotiation delays"] - Internal legal team: [e.g., "one in-house corporate counsel — handles all legal matters for a 65-person company, no dedicated regulatory or IP counsel"] - CRO relationship: [e.g., "one primary CRO managing site activation — CRO uses its own master template which heavily favors CRO rights to site data and publication approval"] - Biggest risk from current process: [e.g., "at 40 sites, the current outside counsel model will cost $400,000 to $560,000 in CTA legal fees alone — the company cannot sustain this cost while also funding Phase II operations"] - Investor concern: [e.g., "lead investor flagged CTA legal cost as a cash burn risk at the last board meeting — expects a scalable internal solution before Series E"] Deliver: 1. A mutual NDA template optimized for clinical site and CRO relationships — covers confidential information definition, permitted disclosure to IRB and regulatory authorities, publication restrictions, return or destruction of confidential information, and a survival clause calibrated to the clinical program timeline 2. A CTA negotiation playbook — covers the four high-frequency contested provisions (publication rights, data IP, indemnification, payment schedule) with the company's preferred position, the minimum acceptable fallback, and the exact language for each fallback position 3. A CRO master service agreement review checklist — 16 items the in-house counsel checks against the CRO's standard template to identify deviations from market-standard positions on data rights, IP ownership, audit access, and termination consequences 4. A site payment schedule template — a standard milestone-based payment structure for Phase II sites covering screening, enrollment, treatment visits, and closeout, with a per-patient and per-visit rate structure that can be adapted to each site's enrollment projection without renegotiating the payment mechanics 5. A CTA self-review protocol for the in-house counsel — a structured 4-hour review process covering the 20 highest-risk CTA provisions, the acceptable and unacceptable positions for each, and the decision rule for escalating to outside counsel versus resolving internally 6. A site activation timeline standard — defines the target CTA execution timeline from site selection to signed agreement at 3 weeks, with the internal milestone, the responsible party, and the escalation trigger if any milestone is missed 7. A CTA deviation log — a running record of every non-standard provision accepted across all active sites, the business justification, and the cumulative IP and indemnification exposure across the full site network 8. A legal cost projection comparison — models the outside counsel cost at 40 sites under the current process versus the internal review model, including the investment in template development and one day of outside counsel review per non-standard site, and presents the net savings in a format suitable for the Series E investor data room **Write every template and protocol component assuming the in-house counsel is the only legal resource and will be managing 40 site relationships simultaneously — every framework must reduce decision fatigue, not increase it, and every fallback position must be specific enough to accept or reject without a second legal opinion.**